Skip to content

Study · Non-randomized trial · 2000

8 results

Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study.

Vahl N, Juul A, Jørgensen JO, Orskov H, Skakkebaek NE, Christiansen JS

The Journal of clinical endocrinology and metabolism1 May 2000Cited by 74 (Europe PMC)

PMID10843168 (opens in a new tab)DOI10.1210/jcem.85.5.6598 (opens in a new tab)PepBankPUB-10843168
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In young adults with childhood-onset GHD, continued GH produced no significant changes in tested parameters, although IGF-I variation suggested possible compliance problems.

    In plain wordsIn young adults with childhood-onset GH deficiency, continued GH produced no significant changes in tested parameters.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeParameters during continued GH
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Patients randomized to continued GH treatment exhibited no significant changes in any parameters tested, but intra- and interindividual variations in insulin-like growth factor (IGF)-I levels could suggest compliance problems.
    2 context sentences
    Summary · context
    We studied a group of nineteen young adults (13 males + 6 females; 16-26 yr old; mean age, 20.2 +/- 0.65 yr) with CO-GHD, in a randomized, parallel, double-blind, placebo-controlled trial for 1 yr, followed by an open phase with GH for 1 yr.
    Summary · context
    All patients received GH therapy at the start of study, and trial medication (GH/placebo) was given in a similar dose.
  2. 02HumanNon-randomized trialEfficacy outcome

    In young adults with childhood-onset GHD, total body fat changed nonsignificantly from 16.2 +/- 2.1 to 17.2 +/- 2.1 kg with continued GH.

    In plain wordsIn young adults with childhood-onset GH deficiency, total body fat did not change significantly during continued GH.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeTotal body fat during continued GH
    Study

    n: not reported in source

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Total body fat
    16.2 kg
    continued GH group, before, +/-2.1
    Total body fat
    17.2 kg
    continued GH group, after 1 yr, +/-2.1

    Source sentences

    Summary
    After discontinuation of GH for 1 yr, an increase in total body fat (TBF, kg), measured by dual-energy x-ray absorptiometry scan, was seen [placebo: 22.7 +/- 2.7 to 26.5 +/- 2.5 (P = 0.01); GH: 16.2 +/- 2.1 to 17.2 +/- 2.1 (not significant)].
    2 context sentences
    Summary · context
    We studied a group of nineteen young adults (13 males + 6 females; 16-26 yr old; mean age, 20.2 +/- 0.65 yr) with CO-GHD, in a randomized, parallel, double-blind, placebo-controlled trial for 1 yr, followed by an open phase with GH for 1 yr.
    Summary · context
    All patients received GH therapy at the start of study, and trial medication (GH/placebo) was given in a similar dose.
  3. 03HumanNon-randomized trialEfficacy outcome

    In young adults with childhood-onset GHD, GH resumption increased IGF-I from 147.8 +/- 33.4 to 452 +/- 76 microg/L (P = 0.001).

    In plain wordsIn young adults with childhood-onset GH deficiency, restarting GH increased IGF-I from the withdrawal level.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-I after GH resumption
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Serum IGF-I
    147.8 microg/L
    before GH resumption, +/-33.4
    Serum IGF-I
    452 microg/L
    after GH resumption, +/-76

    Source sentences

    Summary
    Resumption of GH after placebo was followed by increments in serum IGF-I (microg/L) [from 147.8 +/- 33.4 to 452 +/- 76 (P = 0.001)] and IGF-binding protein 3, as well as in fasting glucose (mmol/L) [4.9 +/- 0.2 vs. 5.3 +/- 0.2 (P = 0.03)].
    2 context sentences
    Summary · context
    We studied a group of nineteen young adults (13 males + 6 females; 16-26 yr old; mean age, 20.2 +/- 0.65 yr) with CO-GHD, in a randomized, parallel, double-blind, placebo-controlled trial for 1 yr, followed by an open phase with GH for 1 yr.
    Summary · context
    All patients received GH therapy at the start of study, and trial medication (GH/placebo) was given in a similar dose.
  4. 04HumanNon-randomized trialEfficacy outcome

    In young adults with childhood-onset GHD, GH resumption increased IGF-binding protein 3.

    In plain wordsIn young adults with childhood-onset GH deficiency, restarting GH increased IGF-binding protein 3 from the withdrawal level.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-binding protein 3 after GH resumption
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Resumption of GH after placebo was followed by increments in serum IGF-I (microg/L) [from 147.8 +/- 33.4 to 452 +/- 76 (P = 0.001)] and IGF-binding protein 3, as well as in fasting glucose (mmol/L) [4.9 +/- 0.2 vs. 5.3 +/- 0.2 (P = 0.03)].
    2 context sentences
    Summary · context
    We studied a group of nineteen young adults (13 males + 6 females; 16-26 yr old; mean age, 20.2 +/- 0.65 yr) with CO-GHD, in a randomized, parallel, double-blind, placebo-controlled trial for 1 yr, followed by an open phase with GH for 1 yr.
    Summary · context
    All patients received GH therapy at the start of study, and trial medication (GH/placebo) was given in a similar dose.
  5. 05HumanNon-randomized trialEfficacy outcome

    In young adults with childhood-onset GHD, GH resumption increased fasting glucose from 4.9 +/- 0.2 to 5.3 +/- 0.2 mmol/L (P = 0.03).

    In plain wordsIn young adults with childhood-onset GH deficiency, restarting GH increased fasting glucose from the withdrawal level.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseFasting glucose after GH resumption
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Fasting glucose
    4.9 mmol/L
    before GH resumption, +/-0.2
    Fasting glucose
    5.3 mmol/L
    after GH resumption, +/-0.2

    Source sentences

    Summary
    Resumption of GH after placebo was followed by increments in serum IGF-I (microg/L) [from 147.8 +/- 33.4 to 452 +/- 76 (P = 0.001)] and IGF-binding protein 3, as well as in fasting glucose (mmol/L) [4.9 +/- 0.2 vs. 5.3 +/- 0.2 (P = 0.03)].
    2 context sentences
    Summary · context
    We studied a group of nineteen young adults (13 males + 6 females; 16-26 yr old; mean age, 20.2 +/- 0.65 yr) with CO-GHD, in a randomized, parallel, double-blind, placebo-controlled trial for 1 yr, followed by an open phase with GH for 1 yr.
    Summary · context
    All patients received GH therapy at the start of study, and trial medication (GH/placebo) was given in a similar dose.
  6. 06HumanNon-randomized trialEfficacy outcome

    In young adults with childhood-onset GHD, GH resumption increased lean body mass from 52.4 +/- 4.9 to 60.7 +/- 5.6 kg (P = 0.006).

    In plain wordsIn young adults with childhood-onset GH deficiency, restarting GH increased lean body mass from the withdrawal level.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLean body mass after GH resumption
    Study

    n: not reported in source

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Lean body mass
    52.4 kg
    before GH resumption, +/-4.9
    Lean body mass
    60.7 kg
    after GH resumption, +/-5.6

    Source sentences

    Summary
    After resumption of GH lean body mass (kg) increased [52.4 +/- 4.9 vs. 60.7 +/- 5.6 (P = 0.006)].
    2 context sentences
    Summary · context
    We studied a group of nineteen young adults (13 males + 6 females; 16-26 yr old; mean age, 20.2 +/- 0.65 yr) with CO-GHD, in a randomized, parallel, double-blind, placebo-controlled trial for 1 yr, followed by an open phase with GH for 1 yr.
    Summary · context
    All patients received GH therapy at the start of study, and trial medication (GH/placebo) was given in a similar dose.
  7. 07HumanNon-randomized trialEfficacy outcome

    In young adults with childhood-onset GHD, GH resumption increased thigh muscle volume from 118.2 +/- 11.7 to 130.0 +/- 10.9 cm2/10 mm (P = 0.002).

    In plain wordsIn young adults with childhood-onset GH deficiency, restarting GH increased thigh muscle volume from the withdrawal level.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseThigh muscle volume after GH resumption
    Study

    n: not reported in source

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Thigh muscle volume
    118.2 cm2/10 mm
    before GH resumption, +/-11.7
    Thigh muscle volume
    130 cm2/10 mm
    after GH resumption, +/-10.9

    Source sentences

    Summary
    Likewise, resumption of GH therapy increased thigh muscle volume and thigh muscle/fat ratio, as assessed by computed tomography [muscle volume (cm2/10 mm): 118.2 +/- 11.7 vs. 130.0 +/- 10.9 (P = 0.002); muscle/fat ratio: 1.33 +/- 0.24 vs. 1.69 +/- 0.36 (P = 0.02)].
    2 context sentences
    Summary · context
    We studied a group of nineteen young adults (13 males + 6 females; 16-26 yr old; mean age, 20.2 +/- 0.65 yr) with CO-GHD, in a randomized, parallel, double-blind, placebo-controlled trial for 1 yr, followed by an open phase with GH for 1 yr.
    Summary · context
    All patients received GH therapy at the start of study, and trial medication (GH/placebo) was given in a similar dose.
  8. 08HumanNon-randomized trialEfficacy outcome

    In young adults with childhood-onset GHD, GH resumption increased the thigh muscle/fat ratio from 1.33 +/- 0.24 to 1.69 +/- 0.36 (P = 0.02).

    In plain wordsIn young adults with childhood-onset GH deficiency, restarting GH increased the thigh muscle-to-fat ratio from the withdrawal level.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseThigh muscle-to-fat ratio after GH resumption
    Study

    n: not reported in source

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Thigh muscle/fat ratio
    1.33 ratio
    before GH resumption, +/-0.24
    Thigh muscle/fat ratio
    1.69 ratio
    after GH resumption, +/-0.36

    Source sentences

    Summary
    Likewise, resumption of GH therapy increased thigh muscle volume and thigh muscle/fat ratio, as assessed by computed tomography [muscle volume (cm2/10 mm): 118.2 +/- 11.7 vs. 130.0 +/- 10.9 (P = 0.002); muscle/fat ratio: 1.33 +/- 0.24 vs. 1.69 +/- 0.36 (P = 0.02)].
    2 context sentences
    Summary · context
    We studied a group of nineteen young adults (13 males + 6 females; 16-26 yr old; mean age, 20.2 +/- 0.65 yr) with CO-GHD, in a randomized, parallel, double-blind, placebo-controlled trial for 1 yr, followed by an open phase with GH for 1 yr.
    Summary · context
    All patients received GH therapy at the start of study, and trial medication (GH/placebo) was given in a similar dose.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.